Prospective, Open-label, Non-significant Risk, Multicenter Study Comparing the Polyp Detection of the Study Device to That of the Colonoscopy Reference
Capso Vision, Inc. · NCT07089615
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 45–75 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 330
- US sites recruiting
- 11
- Study start
- June 26, 2025
- Record last updated
- May 8, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Note: This is the same study protocol as NCT04607746 with slight changes to how the videos will be read and a 2nd generation capsule is being studied.
The purpose of this study is to evaluate the safety and effectiveness of CapsoCam® Colon (CV-3) endoscope system for the detection of colonic polyps and to show that AI-based CADe improves the polyp-detection accuracy and efficiency of capsule video readers. It will use colonoscopy results as a reference.
The participant will
- prep for and swallow a study capsule and then
- prep for and undergo a colonoscopy either the following day or 3-6 weeks later
Being studied: Capsule swallow
Conditions: Colonic Polyps
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 45-75 years of age
- Committed to undergo a colonoscopy.
- Choose to participate and must have signed the IRB-approved informed consent document and agreed to release colonoscopy images and results report to Sponsor
Exclusion Criteria
- Colonoscopy or CT-colonography within the past 5 years that demonstrated no polyps
- Has contraindication for capsule endoscopy or colonoscopy
- Subject is suspected or diagnosed with familial adenomatous polyposis, hereditary non polyposis colon cancer, or any high-risk genetic syndrome
- Subject is suspected or diagnosed with inflammatory bowel disease such as ulcerative colitis or Crohn's disease
- History of incomplete colonoscopy
- Type I or uncontrolled II Diabetes (Uncontrolled defined as HbA1C>6.4 within the past 3 months and/or with history of constipation or gastroparesis).
- Impaired cardiac function assessed as greater than NYHA Class II
- History of small- or large-bowel obstructive condition
- Known history of swallowing disorder, and/or ischemic bowel disease neuropathies and/or radiation enteritis
- Known history of NSAID enteropathy and stricture resulting from taking NSAIDs on a regular basis that, in the opinion of the Investigator, would put the subject at greater risk for capsule endoscope retention
- Known allergy to ingredients used in bowel preparation and boosters
- Daily and/or regular narcotic use
- Decompensated cirrhosis
- Prior abdominal radiation therapy
- Diagnosis of anorexia or bulimia
- History of or suspicion of any of the following: strictures, volvulus or intestinal obstruction, or internal hernias or abdominal surgeries that the Investigator believes should exclude the patient from study participation
- Known or suspected megacolon
- Scheduled to undergo MRI examination within 7 days after ingestion of the capsule
- Has known slow gastric-emptying time or confirmed diagnosis of gastroparesis
- Pregnant or nursing or of child-bearing potential and does not agree to practice medically acceptable methods of contraception. Women of child bearing potential (WOCBP) must have a negative urine pregnancy test at screening.
- Unable to follow or tolerate fasting, bowel preparation, and other study procedures
- Any documented medical or psychological condition or significant concurrent illness which, in the Investigator's opinion, would make it unsafe for the subject to participate in this research study or would affect the validity of the study results
- Are currently enrolled in an interventional clinical study or currently enrolled in or within the last 30 days, a pharmaceutical clinical study
- Chronic constipation as defined by \<3 bowel movements per week, or the use of routine laxatives (other than fiber) to attain regular bowel movements
Recruiting US locations
SB Gastro Clinical Research
Chula Vista, CA 91910
Site contact: Study Coordinator · 619-513-3372 · judy@gastrosb.com
Gastro Care Institute
Lancaster, CA 93534
Site contact: Lead Study Coordinator · 661-529-7550 · Rvargas@gciav.com
Knowledge Research Center
Orange, CA 92868
Site contact: Regulatory/Study Coordinator · 657-247-0087 · j.bermudez@knowledgeresearchcenter.com
Advanced Research Institute
St. Petersburg, FL 33710
Site contact: Study Coordinator · 727-835-3261 · lauren.scott@ariclinical.com
Digestive Health Services
Downers Grove, IL 60515
Site contact: Site Manager · (708) 253-5810 · devang.shah@avicennaclinical.com
Gastroenterology and Internal Medicine Specialists
Lake Barrington, IL 60010
Site contact: Site Manager · 708-253-5810 · devang.shah@avicennaclinical.com
Northshore Center for Gastroenterology
Libertyville, IL 60048
Site contact: Site Manager · 708-253-5810 · devang.shah@avicennaclinical.com
Suburban Gastroenterology
Naperville, IL 60540
Site contact: Site Manager · 708-253-5810 · devang.shah@avicennaclinical.com
Southwest Gastroenterology
Oak Lawn, IL 60453
Site contact: Site Manager · 708-253-5810 · devang.shah@avicennaclinical.com
Gastroenterology Group of Rochester
Rochester, NY 14618
Site contact: Lead Study Coordinator · 585-278-1116 · bvasciannie@ggr1.com
Great Lakes Gastroenterology Research
Mentor, OH 44060
Site contact: Lead Clinical Research Coordinator · 216-387-4966 · susand@greatlakesgastro.net
Study contacts (from the official record)
- Taylor Williamsen Principle CRA/Study Lead · 815-861-9575 · taylor.williamsen@capsovision.com
- Rebecca Petersen Sr. Director of Clinical Affairs · 510-566-8824 · rebecca.petersen@capsovision.com